Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00002565
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇧🇷Faculdade de Medicina do ABC, Sao Paulo, Brazil
🇨🇱Clinica Alemana, Santiago, Chile
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: cytarabineDrug: dexamethasoneDrug: etoposideDrug: idarubicinDrug: ifosfamideDrug: leucovorin calciumDrug: mesnaDrug: pegaspargaseDrug: therapeutic hydrocortisoneDrug: thioguanineDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapyDrug: Methotrexate
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT00002816
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Kaplan Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2009-02-09
- Target Recruit Count
- 60
- Registration Number
- NCT00003758
- Locations
- 🇮🇹
Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, Italy
🇳🇱Groot Ziekengasthuis 's-Hertogenbosch, 's-Hertogenbosch, Netherlands
🇳🇱Sint Joseph Ziekenhuis, Veldhoven, Netherlands
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Rush University Medical Center
- Registration Number
- NCT00003405
- Locations
- 🇺🇸
Rush-Riverside Cancer Center, Kankakee, Illinois, United States
🇺🇸Cook County Hospital, Chicago, Illinois, United States
🇺🇸Rush Cancer Institute, Chicago, Illinois, United States
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 500
- Registration Number
- NCT00002719
- Locations
- 🇮🇹
Azienda Policlinico Umberto Primo, Rome, Italy
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004878
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT00003783
- Locations
- 🇺🇸
West Virginia University Medical School, Charleston Division, Charleston, West Virginia, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00002800
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2012-07-16
- Target Recruit Count
- 106
- Registration Number
- NCT00006122
- Locations
- 🇫🇷
Hotel Dieu de Paris, Paris, France
🇧🇪A.Z. St. Jan, Brugge, Belgium
🇦🇹Innsbruck Universitaetsklinik, Innsbruck, Austria
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Hannover Medical School
- Registration Number
- NCT00002532
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.